Wolf Theiss

WOLF THEISS AND COOLEY ADVISE VIVO CAPITAL AND ORBIMED ON INVESTMENT IN NABRIVA THERAPEUTICS

Nabriva Therapeutics AG announced the successful completion of a USD 120 million Series B financing, led by US based investors Vivo Capital and OrbiMed. International law firm WOLF THEISS advised the new investors on all Austrian legal aspects.

Nabriva Therapeutics AG is an Austrian biotechnology company focused on developing a new class of antibiotics, called pleuromutilins, for the treatment of serious infections caused by resistant bacteria. To progress its lead product, lefamulin, into clinical phase 3 studies and to continue the development of its product pipeline, the company has successfully completed a Series B financing in two tranches of up to USD 120 million. The financing was led by new US based investors Vivo Capital and OrbiMed and included EcoR1 Capital and Boxer Capital of Tavistock Life Sciences. Existing investors HBM, Phase 4 Partners, Wellcome Trust, GLSV and Novartis Venture Fund also participated in the round. Representatives of Vivo Capital and OrbiMed will be joining the Nabriva supervisory board.

WOLF THEISS together with US law firm COOLEY advised the new investors on all legal aspects concerning the transaction. The WOLF THEISS team was led by partners Horst Ebhardt and Hartwig Kienast (Corporate/M&A) and included senior associate Katrin Stauber and associate Nikolaus Koerner (Corporate/M&A), senior associate Sina Steurer (Employment), partner Benjamin Twardosz and associate Bernhard Oreschnik (Tax), partner Roland Marko (IP), senior associate Matthias Schimka (Finance) as well as senior associate Wolfram Schachinger and associate Mario Laimgruber (Regulatory).

For further information please contact

Barbara Fürchtegott
Barbara
Fürchtegott
Public Relations & Communications Manager
T. +43 1 51510 3808
Schubertring 6
1010 Vienna
Austria

Find a Lawyer

Top